Neurocrine Biosciences
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Neurocrine Biosciences - overview
Location
San Diego, CA, US
Primary Industry
Healthcare
About
Neurocrine Biosciences, Inc. focuses on discovering and developing innovative treatments for neurological, neuroendocrine, and neuropsychiatric disorders, providing critical therapeutic options for patients in need. Neurocrine Biosciences specializes in creating treatments for neurological disorders and was founded in San Diego, US. The company has raised USD 10.
00 mn in its latest funding round that occurred on May 23, 1996. The CEO of the company is Kevin Gorman. Neurocrine Biosciences, Inc. specializes in the discovery and development of innovative treatments for patients with neurological, neuroendocrine, and neuropsychiatric disorders.
The company’s core product offerings include therapeutics aimed at addressing conditions such as movement disorders and endocrine-related diseases. These treatments are designed to alleviate suffering for patients who currently lack viable therapeutic options, thus fulfilling a critical need in the healthcare landscape. Neurocrine's solutions serve a diverse clientele that includes healthcare providers, hospitals, and specialty pharmacies, directly impacting end users who seek relief from debilitating conditions. The company is actively engaged in various markets, primarily focusing on regions such as North America and Europe, where the demand for advanced medical treatments in these therapeutic areas is significant.
Neurocrine Biosciences generates revenue through the commercialization of its pharmaceutical products, which are sold primarily through direct-to-consumer channels and partnerships with healthcare providers. The revenue for the most recent year 2024 amounts to USD 2. 33 bn, with an EBITDA of USD 597. 60 mn.
The transaction structure typically involves agreements with hospitals and pharmacies that facilitate the distribution of their therapeutics. Revenue is derived from the sale of flagship products that cater to specific disorders such as tardive dyskinesia. The pricing of these products reflects the specialized nature of the treatments and the research invested in their development. The company’s revenue model is bolstered by ongoing collaborations and potential licensing agreements that enhance its market reach and therapeutic offerings, reinforcing its commitment to addressing significant health needs in the communities it serves.
Neurocrine Biosciences aims to launch new products and expand its market reach in the upcoming years. The company plans to develop additional therapies for neurological disorders, with several products currently in the pipeline for launch by the end of 2025. Furthermore, Neurocrine is targeting expansions into European markets by 2026. The funding raised in its latest round will be utilized to support these initiatives, particularly advancing product development and market entry strategies.
Current Investors
Venrock
Primary Industry
Healthcare
Sub Industries
Biopharmaceuticals, Epidemiology
Website
www.neurocrine.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Neurocrine Biosciences - timeline of key events
Neurocrine Biosciences - financials
| Fiscal Year Ended | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 77,413,000 | 53,140,000 | 2,919,000 | - | 19,769,000 | 15,000,000 | 161,626,000 | 451,240,000 | 788,087,000 | 1,045,900,000 | 1,133,500,000 | 1,488,700,000 | - | - | - |
| % Revenue Growth (YoY) | - | (31.4%) | (94.5%) | (100.0%) | - | (24.1%) | 977.5% | 179.2% | 74.6% | 32.7% | 8.4% | 31.3% | - | - | - |
| EBITDA (USD) | 36,957,000 | 5,240,000 | (46,164,000) | (59,792,000) | (87,161,000) | (142,399,000) | (115,420,000) | 61,246,000 | 98,081,000 | 193,000,000 | 102,500,000 | 265,800,000 | - | - | - |
| Operating Income (USD) | 33,922,000 | 1,448,000 | (49,678,000) | (64,411,000) | (94,202,000) | (147,372,000) | (131,361,000) | 36,895,000 | 72,283,000 | 163,000,000 | 102,500,000 | 249,000,000 | - | - | - |
| Operating Margin | 43.8% | 2.7% | (1701.9%) | - | (476.5%) | (982.5%) | (81.3%) | 8.2% | 9.2% | 15.6% | 9.0% | 16.7% | - | - | - |
| % EBITDA Margin | 47.7% | 9.9% | (1581.5%) | - | (440.9%) | (949.3%) | (71.4%) | 13.6% | 12.4% | 18.5% | 9.0% | 17.9% | - | - | - |
| NET Income (USD) | 37,571,000 | 5,025,000 | (46,090,000) | (60,542,000) | (88,929,000) | (141,090,000) | (142,542,000) | 21,111,000 | 37,012,000 | 407,300,000 | 89,600,000 | 154,500,000 | - | - | - |
| % Net Margin | 48.5% | 9.5% | (1579.0%) | - | (449.8%) | (940.6%) | (88.2%) | 4.7% | 4.7% | 38.9% | 7.9% | 10.4% | - | - | - |
Neurocrine Biosciences - employee data
Neurocrine Biosciences - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Chairman of the Board | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.